Projected Price to Earnings: Maze Therapeutics Corp (MAZE)

Official company branding of Maze Therapeutics (MAZE)

The forward P/E ratio of Maze Therapeutics Inc (MAZE) shows a metric value of 0.00, while the business relies on venture investments without a stable cash flow. Maze Therapeutics Inc (MAZE) utilizes IT solutions to accelerate the discovery of innovative drugs. In the long term, the Compass AI system will provide absolute pricing power by creating unique methods for correcting genetic defects.

mazetx.com - MAZE Market Cap to Future Earnings Ratio (period 02/01/2025 - 11/17/2026)

Summary analytical data breakdowns for mazetx.com (MAZE)

- stock quotes and analyst forecast:
- company stock exchange capitalization indicators:
Fundamental valuation:Maze Therapeutics, Inc.
Brand item of Maze Therapeutics Inc

Forward P/E determines the share price based on expected future earnings, measuring the degree of market optimism. The forward P/E dynamics of Maze Therapeutics Inc (MAZE) allow for a real-time assessment of the risk of overpaying for future success. This ratio confirms financial stability during the scaling of operational activities. For Maze Therapeutics Inc (MAZE), this reflects the capitalization of the potential of the Compass AI-mapping platform. The indicator links the current price to the prospects of releasing targeted drugs for Pompe disease.

Analysis of competing companies

Projected Price to Earnings TEM (Tempus AI, Inc)|Qiagen Group (QGEN) - Forward Price to Earnings Multiple|Future Price to Earnings ionispharma.com IONS|Market Cap to Projected Earnings Repligen Corporation (RGEN)|RNA: Projected Price to Earnings|Future Price to Earnings Multiple CRSP (CRISPR Therapeutics Corp)|WGS: Forward P/E Multiple|Projected Price to Earnings Ratio Ultragenyx Corp (RARE)|BEAM (Beam Therapeutics Inc) - Forward P/E Multiple|SRPT: Future Price to Earnings Multiple|Future Price to Earnings Twist Bioscience Corp (TWST)|Projected Price to Earnings 10x Genomics Inc TXG|Intellia Therapeutics, Inc. - Projected Price to Earnings|Future Price to Earnings Multiple STOK|BLFS - Future Price to Earnings|Wave Life Sciences (WVE) - Projected Price to Earnings|SION: Forward P/E Multiple|PRME - Market Cap to Projected Earnings|Projected Price to Earnings TSHA|QURE - Forward Price to Earnings Multiple|Forward P/E Multiple MGTX|Market Cap to Projected Earnings regenxbio.com|Forward P/E Multiple SLDB (Solid Biosciences Inc)|OCGN: Price to Future Earnings Ratio|PACB - Future Price to Earnings|Benitec (BNTC) - Projected Price to Earnings|DSGN: Forward P/E Multiple|RCKT: Market Cap to Future Earnings Ratio|FDMT (4D Molecular Therapeutics, Inc.) - Forward P/E Multiple|lexeotx.com (LXEO) - Market Cap to Projected Earnings|Forward P/E Multiple KRRO|Projected Price to Earnings Editas Medicine, Inc. EDIT|Future Price to Earnings silence-therapeutics.com SLN|PRQR: Price to Future Earnings Ratio|CDXS - Future Price to Earnings|Market Cap to Projected Earnings Sangamo Therapeutics, Inc. SGMO|NAUT (nautilus.bio) - Projected Price to Earnings|Projected Price to Earnings Ratio Metagenomi, Inc. (MGX)|Projected Price to Earnings DTIL|Price to Future Earnings Ratio GBIO (generationbio.com)|Future Price to Earnings Boundless Bio, Inc (BOLD)|Forward P/E Multiple Exicure Inc. (XCUR)|Imunon, Inc. - Projected Price to Earnings|PHIO: Price to Future Earnings Ratio|MBIO - Future Price to Earnings|Price to Expected Earnings Ratio RNAZ|Bionano Genomics, Inc. (BNGO) - Future Price to Earnings|Applied DNA Sciences, Inc. (APDN) - Forward P/E Multiple|BLUE (bluebirdbio.com) - Forward P/E Multiple|Price to Future Earnings Ratio IPA (ImmunoPrecise Antibodies)|Forward P/E Multiple OMGA|Projected Price to Earnings Singular Genomics Systems OMIC|Forward P/E Multiple RGLS (regulusrx.com)|Syros Pharmaceuticals Inc. (SYRS) - Projected Price to Earnings Ratio|TBIO: Projected Price to Earnings|Future Price to Earnings Multiple TCON (TRACON)|UBX: Forward P/E Multiple